Editors
Cristiana Sessa
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Luca Gianni
Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Marina Garassino
Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy
Henk van Halteren
Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands
Contributors
Chapter 1: Preclinical Drug Development: Translating Basic Research into Clinical Work
Stathis A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Siu L.L. Drug Development Program, Princess Margaret Hospital, Toronto, Canada
Le Tourneau C. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France
Chapter 2: Pharmacokinetics and Pharmacodynamics: Main Concepts and Clinical Applications
Calvert A.H. UCL Cancer Institute, University College London, London, UK
Chapter 3: Alkylating Agents
Damia G. Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
Garassino M. Oncology Department, Istituto Nazionale dei Tumori, Milan, Italy
Chapter 4: Platinum Agents
Razak A.R.A. Drug Development Program, Princess Margaret Hospital, Toronto, Canada
Calvert A.H. UCL Cancer Institute, University College London, London, UK
Chapter 5: Antimetabolites
Martínez M.T. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
Roselló S. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
Cervantes A. Department of Hematology and Medical Oncology; Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
Chapter 6: Topoisomerase-I and –II Inhibitors
Locatelli A. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Viganò L. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Chapter 7: Tubulin-active Agents
Le Tourneau C. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France
Diéras V. Department of Medical Oncology, Clinical Trial Unit, Institut Curie, Paris, France
Chapter 8: Miscellaneous
Christinat A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Chapter 9: Hormonal Pathways Modulators of the Reproductive System
Tosi D. Medical Oncology Department, CRLC Val d’Aurelle-Paul Lamarque, Montpellier, France
Durigova A. Medical Oncology Department, CRLC Val d’Aurelle- Paul Lamarque, Montpellier, France
Barrière J. Centre Antoine Lacassagne, Nice, France
Chapter 10: Growth Factor Receptor Targeting: Anti-HER and Anti-IGF-IR
Dienstmann R. Vall d’Hebron Institute of Oncology, Barcelona, Spain
De Dosso S. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Tabernero J. Vall d’Hebron Institute of Oncology, Barcelona, Spain
Chapter 11: Tumour Vessel Targeting
Del Conte G. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Chapter 12: Downstream Receptor Targeting: P13K, mTOR, K-ras, BRAF, MEF
Fasolo A. Ospedale San Raffaele, IRCCS, Unit of New Drugs and Innovative Therapies, Department of Medical Oncology, Milan, Italy
Chapter 13: Cancer-related Receptor Targeting: Bcr-Abl, KIT, MET
Rusconi P. Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
Broggini M. Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
Chapter 14: Epigenetic Therapy: DNA Methyltransferase Inhibitors and Histone Deacetylase Inhibitors
Stathis A. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Lobetti-Bodoni C. Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Catapano C. Institute of Oncology Research, Bellinzona, Switzerland
Chapter 15: Proteasome Inhibitors
Driessen C. Interdisziplinare Medizinische Dienste, Kantonsspital St Gallen, St Gallen, Switzerland
Chapter 16: Monoclonal Antibodies for Targeted Treatment of Lymphoproliferative Neoplasias
Guidetti A. Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan; Medical Oncology, University of Milan, Milan, Italy
Giacomini A. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy
Locatelli S.L. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy
Carlo-Stella C. Medical Oncology, University of Milan, Milan; Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano (Milan), Italy
Chapter 17: Immunomodulatory Drugs and Cytokines
Haanen J. Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Blank C. Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
